FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Addr Davidson N | 1 and 1 a | | 2. Issuer Name and Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [VRCA] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner |
|--------------------------------|---|----------|---|--|
| (Last) | (First) PHARMACEUTI | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2019 | Officer (give title Other (specify below) below) |
| | HARMACEUTI | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person |
| (Street) WEST CHESTER | РА | 19380 | | Form filed by More than One Reporting Person |
| (City) | (State) | (Zip) | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | | | 4. Securities Disposed Of 5) | | | 5. Amount of Securities Beneficially Owned Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | of Indirect Beneficial Ownership |
|---------------------------------|--|---|-------------------------|---|------------------------------------|---------------|-------------------------------|--|--|--|
| | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | (1150.4) | (Instr. 4) |
| Common Stock | 03/01/2019 | | S ⁽¹⁾ | | 3,690 | D | \$12.12 ⁽²⁾ | 2,908,772 | D | |
| Common Stock | 03/01/2019 | | S ⁽¹⁾ | | 1,700 | D | \$12.77(3) | 2,907,072 | D | |
| Common Stock | 03/04/2019 | | S ⁽¹⁾ | | 9,740 | D | \$12.67 ⁽⁴⁾ | 2,897,332 | D | |
| Common Stock | 03/04/2019 | | S ⁽¹⁾ | | 1,400 | D | \$13.38(5) | 2,895,932 | D | |
| Common Stock | 03/05/2019 | | S ⁽¹⁾ | | 6,800 | D | \$12 ⁽⁶⁾ | 2,889,132 | D | |
| Common Stock | 03/05/2019 | | S ⁽¹⁾ | | 2,500 | D | \$12.72(7) | 2,886,632 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transact Code (In 8) | | of Deriv Secur Acqu (A) or Dispo of (D) | vivative (Month/Day/Year) curities quired) or sposed (D) str. 3, 4 | | Amour Securi Underl Deriva Securi | 7. Title and 8. P Amount of of Securities Der Underlying Sec Derivative (Ins Security (Instr. 3 and 4) | | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | Ownership Form: Direct (D) | Beneficial Ownership | |
|---|---|--|---|----------------------------------|---|---|---|---------------------|---|--|--|--|----------------------------------|-------------------------|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |

Explanation of Responses:

1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$11.45 to \$12.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$12.46 to \$13.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$12.09 to \$13.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$13.15 to \$13.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$11.66 to \$12.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$12.66 to \$12.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

/s/ Mark Ballantyne, Attorney-<u>in-Fact</u> 03/05/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.